Roivant Sciences (ROIV) Return on Capital Employed (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Return on Capital Employed came in at 47.91% in Q4 2025, down 11785.0% YoY from N/an in Q4 2024, and down 42.58% on a QoQ basis from 33.6% in Q3 2025.
Roivant Sciences (ROIV) Return on Capital Employed (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Return on Capital Employed data on file, last reported at 47.91% in Q4 2025.
- Quarterly Return on Capital Employed fell 11785.0% year-over-year to 47.91% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 47.91% (down 11785.0% YoY) and the FY2026 annual result came in at 9.93%, up 843.0% from the prior year.
- Return on Capital Employed slipped to 47.91% in Q4 2025, from 33.6% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 84.42% in Q4 2023 to a low of 117.24% in Q4 2022.
- A 5-year average of 30.2% and a median of 47.91% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed surged 20166 bps — and 2025, when it sank 11785 bps.
- Tracing ROIV's Return on Capital Employed over 5 years: stood at 78.22% in 2021, then tumbled by 50 bps to 117.24% in 2022, then surged by 172 bps to 84.42% in 2023, then fell by 17 bps to 69.94% in 2024, then slumped by 169 bps to 47.91% in 2025.
- The last three Return on Capital Employed figures came in at 47.91% (Q4 2025), 33.6% (Q3 2025), and 28.26% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -36.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.13% |
| Dec 31, 2025 | -47.91% |
| Sep 30, 2025 | -33.60% |
| Jun 30, 2025 | -28.26% |
| Dec 31, 2024 | 69.94% |
| Sep 30, 2024 | 77.13% |
| Jun 30, 2024 | 66.13% |
| Dec 31, 2023 | 84.42% |
| Sep 30, 2023 | -81.55% |
| Jun 30, 2023 | -78.96% |
| Dec 31, 2022 | -117.24% |
| Sep 30, 2022 | -107.12% |
| Jun 30, 2022 | -97.44% |
| Dec 31, 2021 | -78.22% |
| Sep 30, 2021 | -50.68% |
| Jun 30, 2021 | -29.59% |